Chronic Insomnia Market Expected to Thrive at a CAGR of 7.29% for the Study Period 2018-2030 in the 7MM, Estimates DelveInsight
LAS VEGAS, April 22, 2021 /PRNewswire/ -- The Chronic Insomnia Market report offers a comprehensive analysis of the disease overview, its causes, signs/ symptoms, and diagnosis modalities. The report highlights the available treatment, pipeline therapies, and factors changing the Chronic Insomnia market landscape during the study period 2018-30 in the 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan).
The Chronic Insomnia market size insights report is designed to identify and grab true opportunities in the Chronic Insomnia market landscape, help clients form collaborations and ink deals that give them a competitive advantage and plan strategic moves to yield maximum returns.
Some of the key takeaways from the Chronic Insomnia market report:
- The total diagnosed Chronic Insomnia prevalent population in the 7MM countries was estimated to be 5,585,128 cases in 2020. Further, it is estimated that the diagnosed prevalence will rise ascribed to it being an easy-to-diagnose condition and increasing awareness of the disease.
- The US reported the highest Chronic Insomnia patient pool, more than 2,500,000 in 2020.
- The US accounted for the maximum share of the Chronic Insomnia market size, approximately 66.42% of the overall market size of Chronic Insomnia in 2020.
- Key pharmaceutical companies energetically working in the Chronic Insomnia market are Idorsia Pharmaceuticals, Janssen Research & Development/Minerva Neurosciences, and Sequential Medicine, among others.
- Key pipeline therapies set to place their foot in the market during the forecast period 2021-30 include Daridorexant, Seltorexant, SM-1, and several others.
Interested in learning more? Request for Sample @ Chronic Insomnia Market Analysis and Forecast
Insomnia is the most common sleep disorder with huge socio-economic costs. According to the third edition of the International Classification of Sleep Disorders (ICSD-3), it is characterized by difficulty in either initiating sleep, maintaining sleep continuity, or poor sleep quality. However, Chronic Insomnia is more complex, accompanied by daytime impairment of cognition, mood, or performance.
Various studies worldwide have shown the prevalence of insomnia in 10–30% of the population, some even as high as 50–60%. As per DelveInsight's Chronic Insomnia epidemiological analysis, Chronic Insomnia is slightly more prevalent among females than males.
The Chronic Insomnia market report offers historical and forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:
- Chronic Insomnia Prevalent Cases
- Chronic Insomnia Diagnosed Prevalent Cases
- Gender-specific Chronic Insomnia Cases
- Age-specific Chronic Insomnia Cases
For more insights, visit Chronic Insomnia Epidemiological Analysis and Forecast
Chronic Insomnia Market
The primary goal of the Chronic Insomnia market is to improve sleeping habits and alleviate symptoms such as distress and dysfunction. It can be managed with the help of psychological therapy, pharmacologic therapy, or a combination of both.
Psychological therapy options present in the Chronic Insomnia market include cognitive behavioral therapy for insomnia (CBT-I), multicomponent behavioral therapy or brief behavioral therapy (BBT) for insomnia, and other interventions, such as stimulus control, relaxation strategies, and sleep restriction.
Benzodiazepines are frequently prescribed to treat insomnia. Five benzodiazepines (estazolam, flurazepam, quazepam, temazepam, and triazolam) are in market as the FDA-approved medications for insomnia management. Non-benzodiazepine hypnotics include zopiclone, zolpidem, and zaleplon. Orexin receptor antagonists, including Dayvigo and Belsomra, recently gained popularity in the Chronic Insomnia market therapy.
Reach out to us @ Chronic Insomnia Market Landscape, Growth, Drivers and Barriers
However, several limitations exist in the present Chronic Insomnia market. Lack of in-depth clinical training in current medical curricula has resulted in delayed or misdiagnosed and improper treatment plans for patients. An increased understanding and screening of insomnia disorder by health care professionals could result in broader public knowledge of insomnia disorder and sleep health.
Reach out for Consulting Solutions into Healthcare and Medical Vertical @ Healthcare Business Consulting Solutions
Chronic Insomnia Pipeline Therapies
Daridorexant: Idorsia Pharmaceuticals
Seltorexant: Janssen Pharmaceuticals
SM-1: Sequential Medicine
Scope of the Report
Coverage: 7MM (the US, EU5, and Japan)
Study Period: 2018-30
Key Companies: Idorsia Pharmaceuticals, Janssen Pharmaceuticals, Sequential Medicine
Key Chronic Insomnia Pipeline Therapies: Daridorexant, Seltorexant, SM-1
Chronic Insomnia Market Segmentation: By Geography, By Chronic Insomnia Therapies
Analysis: Comparative and conjoint analysis of Chronic Insomnia emerging therapies
Tools used: SWOT analysis, Conjoint Analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.
Get in touch to know more about the report scope @ Chronic Insomnia Market Landscape and Future Trends
Table of Contents
Chronic Insomnia Market Overview at a Glance
Executive Summary of Chronic Insomnia
Chronic Insomnia Epidemiology and Patient Population
Chronic Insomnia Patient Journey
Organizations contributing to Chronic Insomnia
Treatment Algorithm, Current Treatment, and Medical Practices
Key Endpoints in Chronic Insomnia Clinical Trials
Chronic Insomnia Marketed Therapies
Chronic Insomnia Emerging Therapies
Other Chronic Insomnia Promising Therapies
Chronic Insomnia: 7 Major Market Analysis
Access and Reimbursement Overview of Chronic Insomnia
Chronic Insomnia Market Drivers
Chronic Insomnia Market Barriers
Chronic Insomnia Market Access
Know more about the report offerings @ Chronic Insomnia Market Insights, and Forecast
Browse Through Related Reports
Read more about Sleep Disorders, their symptoms, treatments and key companies working in the space.
DelveInsight's "Acute ischemic stroke (AIS) Market Insights, Epidemiology, and Market Forecast-2030" report.
DelveInsight's 'Acute Pancreatitis (AP) Market Insights, Epidemiology, and Market Forecast —2030' report.
DelveInsight's "Anesthetic Effect Market Insights, Epidemiology, and Market Forecast-2030" report.
DelveInsight's "Autism Spectrum Disorder (ASD) Market Insights, Epidemiology, and Market Forecast-2030" report.
DelveInsight's "Brain Hemorrhage Market Insights, Epidemiology, and Market Forecast-2030" report.
DelveInsight's "Cryptococcal Meningitis Market Insights, Epidemiology, and Market Forecast-2030" report.
DelveInsight's "Chronic Traumatic Encephalopathy (CTE) Market Insights, Epidemiology, and Market Forecast-2030" report.
DelveInsight's "Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast-2030" report.
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
View original content:http://www.prnewswire.com/news-releases/chronic-insomnia-market-expected-to-thrive-at-a-cagr-of-7-29-for-the-study-period-20182030-in-the-7mm-estimates-delveinsight-301275128.html
SOURCE DelveInsight Business Research LLP
Upcoming Life Sciences Events
- May 2021
- Shanghai: ChinaBio® Partnering Forum
- European Health-tech Innovation Week
- 7th Annual Immuno-Oncology Innovation Forum